PE20231844A1 - DECONGESTANT AND BILASTINE DRUG DELIVERY SYSTEM - Google Patents
DECONGESTANT AND BILASTINE DRUG DELIVERY SYSTEMInfo
- Publication number
- PE20231844A1 PE20231844A1 PE2023000151A PE2023000151A PE20231844A1 PE 20231844 A1 PE20231844 A1 PE 20231844A1 PE 2023000151 A PE2023000151 A PE 2023000151A PE 2023000151 A PE2023000151 A PE 2023000151A PE 20231844 A1 PE20231844 A1 PE 20231844A1
- Authority
- PE
- Peru
- Prior art keywords
- bilastine
- decongestant
- weight
- core
- present
- Prior art date
Links
- 229960004314 bilastine Drugs 0.000 title abstract 3
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000850 decongestant Substances 0.000 title abstract 3
- 238000012377 drug delivery Methods 0.000 title 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 3
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 3
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 3
- 229920013820 alkyl cellulose Polymers 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 235000010980 cellulose Nutrition 0.000 abstract 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229960001802 phenylephrine Drugs 0.000 abstract 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 1
- 229960003908 pseudoephedrine Drugs 0.000 abstract 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a una composicion farmaceutica oral multicapa que comprende: un nucleo matricial, que comprende un descongestivo seleccionado de pseudoefedrina, fenilefrina y sales farmaceuticas de las mismas, y una combinacion de al menos dos derivados de celulosa seleccionados de alquilcelulosas C1-6, hidroxialquilcelulosas C1-6, carboxialquilcelulosas C1-3 y celulosa microcristalina, en la que al menos hay presente hidroxipropilmetilcelulosa entre 15 y 40% en peso de hidroxipropilmetilcelulosa y hay presente celulosa microcristalina en una cantidad entre 20 y 50% en peso; y una primera capa que cubre dicho nucleo, que comprende un derivado de celulosa seleccionado de alquilcelulosas C1-6, hidroxialquilcelulosas C1-6, carboxialquilcelulosas C1-3 y celulosa microcristalina, en la que hay presente etilcelulosa. Ademas, una segunda capa que cubre la primera capa, de liberacion inmediata, que comprende de 1 a 20 % en peso de bilastina con respecto al peso total del nucleo. Este sistema de liberacion controlada de farmacos descongestivos y bilastina se usa para tratar signos y sintomas asociados a estados alergicos y/o infamatorios de la piel o de las vias respiratorias altas y bajas.Referring to a multilayer oral pharmaceutical composition comprising: a matrix core, comprising a decongestant selected from pseudoephedrine, phenylephrine and pharmaceutical salts thereof, and a combination of at least two cellulose derivatives selected from C1-6 alkylcelluloses, C1-6 hydroxyalkylcelluloses, C1-3 carboxyalkylcelluloses and microcrystalline cellulose, wherein at least hydroxypropylmethylcellulose is present between 15 and 40% by weight of hydroxypropylmethylcellulose and microcrystalline cellulose is present in an amount between 20 and 50% by weight; and a first layer covering said core, comprising a cellulose derivative selected from C1-6 alkylcelluloses, C1-6 hydroxyalkylcelluloses, C1-3 carboxyalkylcelluloses and microcrystalline cellulose, in which ethylcellulose is present. In addition, a second layer covering the first layer, of immediate release, comprising 1 to 20% by weight of bilastine with respect to the total weight of the core. This controlled release system of decongestant drugs and bilastine is used to treat signs and symptoms associated with allergic and/or inflammatory conditions of the skin or upper and lower respiratory tract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382701 | 2020-07-30 | ||
| PCT/EP2021/071244 WO2022023463A1 (en) | 2020-07-30 | 2021-07-29 | Decongestant drug delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231844A1 true PE20231844A1 (en) | 2023-11-21 |
Family
ID=72039495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000151A PE20231844A1 (en) | 2020-07-30 | 2021-07-29 | DECONGESTANT AND BILASTINE DRUG DELIVERY SYSTEM |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4188339A1 (en) |
| CL (1) | CL2023000262A1 (en) |
| CO (1) | CO2023002166A2 (en) |
| CR (1) | CR20230109A (en) |
| DO (1) | DOP2023000017A (en) |
| EC (1) | ECSP23010160A (en) |
| PE (1) | PE20231844A1 (en) |
| WO (1) | WO2022023463A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230248667A1 (en) * | 2022-02-04 | 2023-08-10 | Aurobindo Pharma Ltd | Extended release compositions of pseudoephedrine or its pharmaceutically acceptable salt thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| ES2048109B1 (en) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | PROCEDURE FOR THE PREPARATION OF NEW PIPERIDIC DERIVATIVES OF BENCIMIDAZOLE. |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| ES2124167B1 (en) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | NEW DERIVATIVES OF BENZMIDAZOLE WITH ANTIHISTAMINE ACTIVITY. |
| AU2277101A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| NZ539915A (en) * | 2002-12-11 | 2007-09-28 | Pfizer Prod Inc | Controlled-release of an active substance into a high fat environment |
| US20070014855A1 (en) * | 2005-07-12 | 2007-01-18 | Rahul Gawande S | Stable desloratadine compositions |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| MX2011005899A (en) | 2011-06-03 | 2013-01-10 | Senosiain S A De C V Lab | Pharmaceutical composition with non-sedative antihistamine and combinations thereof. |
| CN104000822A (en) * | 2014-06-10 | 2014-08-27 | 合肥医工医药有限公司 | Compound cold medicinal composition containing bilastine |
| MX2015003937A (en) * | 2015-03-26 | 2016-09-26 | Alparis Sa De Cv | Pharmaceutical composition including a non-sedating antihistaminic and an anti-inflammatory immunosuppressant. |
-
2021
- 2021-07-29 WO PCT/EP2021/071244 patent/WO2022023463A1/en not_active Application Discontinuation
- 2021-07-29 PE PE2023000151A patent/PE20231844A1/en unknown
- 2021-07-29 CR CR20230109A patent/CR20230109A/en unknown
- 2021-07-29 EP EP21755715.6A patent/EP4188339A1/en not_active Withdrawn
-
2023
- 2023-01-26 CL CL2023000262A patent/CL2023000262A1/en unknown
- 2023-01-27 DO DO2023000017A patent/DOP2023000017A/en unknown
- 2023-02-13 EC ECSENADI202310160A patent/ECSP23010160A/en unknown
- 2023-02-27 CO CONC2023/0002166A patent/CO2023002166A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188339A1 (en) | 2023-06-07 |
| CL2023000262A1 (en) | 2023-10-06 |
| WO2022023463A1 (en) | 2022-02-03 |
| CR20230109A (en) | 2023-05-11 |
| ECSP23010160A (en) | 2023-03-31 |
| DOP2023000017A (en) | 2023-02-28 |
| CO2023002166A2 (en) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arakawa et al. | Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline | |
| Kamisah et al. | Cardioprotective properties of kaempferol: a review | |
| Ha et al. | Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo | |
| Imran et al. | Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review | |
| AR067326A1 (en) | IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE | |
| JP2007515423A5 (en) | ||
| JP2016518388A5 (en) | ||
| JP2012515754A5 (en) | ||
| Hong et al. | Anti-inflammatory and neuroprotective effects of morin in an MPTP-induced Parkinson’s disease model | |
| Ren et al. | Sevoflurane postconditioning provides neuroprotection against brain hypoxia–ischemia in neonatal rats | |
| PE20231844A1 (en) | DECONGESTANT AND BILASTINE DRUG DELIVERY SYSTEM | |
| Feng et al. | Silymarin ameliorates the disordered glucose metabolism of mice with diet-induced obesity by activating the hepatic SIRT1 pathway | |
| US20200016228A1 (en) | Orally administered composition for treating cystic fibrosis, copd, asthma and other inflammatory conditions | |
| JP2020536121A5 (en) | ||
| JP2018524306A (en) | Enantiomers of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine (ANAVEX2-73) and their use in the treatment of Alzheimer type and other injuries regulated by sigma 1 receptor | |
| Sharma et al. | Efficacy of add-on Ayurveda and Yoga intervention in health care workers of tertiary care hospital during COVID-19: Randomized controlled trial | |
| Gatzke et al. | Nitroglycerin application and coronary arteriogenesis | |
| Liu et al. | Menthol-modified quercetin liposomes with brain-targeting function for the treatment of senescent Alzheimer’s disease | |
| Xiang et al. | Anti-inflammatory effect of acetylpuerarin on eicosanoid signaling pathway in primary rat astrocytes | |
| HRP20130225T1 (en) | Retardformulation comprising 3-(2-dimethylaminomethylcyclohexyl) phenol | |
| Ansari et al. | Immune boosting and anti-influenza effects of an Unani decoction in influenza like illness and COVID-19 like epidemics: a rationale approach | |
| Ravshanova et al. | Studies of acute toxicity of the drug" Analfenon" for use in tablet form | |
| Rivera-Guzmán et al. | Transient AV block as a hemodynamic complication of the influenza A virus: a case report | |
| AR075058A1 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES AND MANUFACTURING PROCESS | |
| Bird-Lake | Severe transient left ventricular dysfunction induced by thyrotoxicosis |